about
The frameshift signal of HIV-1 involves a potential intramolecular triplex RNA structureNMR structure of a biologically active peptide containing the RNA-binding domain of human immunodeficiency virus type 1 TatThe site of antiviral action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in human lymphocytesThe human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapyPathogenesis of human immunodeficiency virus infectionRegulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factorsIn vitro interaction of the human immunodeficiency virus type 1 Tat transactivator and the general transcription factor TFIIB with the cellular protein TAPMolecular cloning and characterization of a cellular protein that interacts with the human immunodeficiency virus type 1 Tat transactivator and encodes a strong transcriptional activation domainLentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactorImmunovirological parameters and cytokines in HIV infectionMutations in the nuclear export signal of human ran-binding protein RanBP1 block the Rev-mediated posttranscriptional regulation of human immunodeficiency virus type 1Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatmentPentoxifylline and other protein kinase C inhibitors down-regulate HIV-LTR NF-kappa B induced gene expressionOrigins of genes: "big bang" or continuous creation?The central domain of the matrix protein of HIV-1: influence on protein structure and virus infectivity.High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41.Targeting the HIV trans-activation responsive region--approaches towards RNA-binding drugs.Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus.Human immunodeficiency virus-1-tat induces matrix metalloproteinase-9 in monocytes through protein tyrosine phosphatase-mediated activation of nuclear transcription factor NF-kappaB.Identification of c-fos-responsive elements downstream of TAR in the long terminal repeat of human immunodeficiency virus type-1.Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation.Fluorescent ribonucleoside as a FRET acceptor for tryptophan in native proteins.Chromatin disruption and histone acetylation in regulation of the human immunodeficiency virus type 1 long terminal repeat by thyroid hormone receptorCD39 is an ecto-(Ca2+,Mg2+)-apyrase.Adenosyl radical: reagent and catalyst in enzyme reactions.Delivery of novel macromolecular drugs against HIV-1.Molecular basis of intracistronic complementation in the Passover locus of DrosophilaMyosin-actin interaction plays an important role in human immunodeficiency virus type 1 release from host cells.Preparation of oligoribonucleotides containing 4-thiouridine using Fpmp chemistry. Photo-crosslinking to RNA binding proteins using 350 nm irradiationExon2 of HIV-2 Tat contributes to transactivation of the HIV-2 LTR by increasing binding affinity to HIV-2 TAR RNA.Rev of human immunodeficiency virus and Rex of the human T-cell leukemia virus type I can counteract an mRNA downregulatory element of the transferrin receptor mRNA.Levels of major selenoproteins in T cells decrease during HIV infection and low molecular mass selenium compounds increase.Differential expression of mRNAs for JC virus large and small tumor antigens in brain tissues from progressive multifocal leukoencephalopathy patients with and without AIDS.Transcriptional activation in vitro by the human immunodeficiency virus type 1 Tat protein: evidence for specific interaction with a coactivator(s).Restriction of human immunodeficiency virus type 1 production in a human astrocytoma cell line is associated with a cellular block in Rev function.Repression in vitro, by human adenovirus E1A protein domains, of basal or Tat-activated transcription of the human immunodeficiency virus type 1 long terminal repeat.Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes.Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytesIdentification and mapping of inhibitory sequences in the human immunodeficiency virus type 2 vif gene.
P2860
Q24534107-40345C0D-5CED-4FF3-9061-A93734F3431BQ24564152-BDC06115-7B83-4563-AD4F-F0F99FB0C302Q24564579-CCB3EEFC-CCED-4E5B-9978-2E921AC0AC57Q24607992-4DCC6726-8E47-4E15-B898-3BF9A8E0536FQ24634681-966BCA35-A021-44B0-89BC-BFED7EBDA7D5Q24651506-906B70D5-0714-4A0E-8C71-14162363ED62Q24675459-2ECEA80B-AE49-415F-9635-43367FBD0D58Q24675484-36D7F680-5F30-407C-9229-C48F4D4AD998Q24676286-D2B98A82-DC82-4E33-866A-3DF745F13DFDQ26829264-10DA68E1-9A07-402C-875B-C142BCF38A63Q28235567-EECDC5B2-B14D-4542-930E-12688F70ACE7Q28342742-60AD9ADE-0FFA-49F4-92A8-2FAEA1523866Q28369408-F8452201-2801-420F-874E-C75BDE81A5E1Q28379107-9474208C-4D21-4F58-B08A-EF9C4FBF0DAEQ28775832-43F4B93A-45E1-40E6-95EA-9F0A900B2DF2Q30341481-1E4D5E87-F623-4A22-A8C6-37C447EC9F49Q30846393-C8386888-8CF6-49A1-BABC-FC089C5A3B5AQ33193600-292DC0C7-0682-4698-A630-1C4590CA2328Q33772234-7628AC67-A580-4C3F-BEA9-123BB584C8DDQ33882080-546324AA-006F-4CDE-A416-AC07221CC586Q33902078-A4AEFC78-75BA-42B7-B68D-E843C92006E2Q34057748-B5D36E49-20AF-4A7A-91AA-9D1F44AC8BEBQ34138992-516985C8-49D7-4635-8C7D-A0B9323DED70Q34281377-083B6429-F034-4FA0-B147-AD870F581F7DQ34378982-955A5A18-34F9-486A-90F2-93A1E9D8DBF7Q34447149-276D1748-B3A3-4068-BB4B-36EFC5594C47Q34452681-16DC9C28-3764-4B8A-8093-FCF7E1E8FAA2Q34561535-6D110385-951A-48F1-8CDC-B3263D7832D1Q34562034-7620C7DE-586B-4007-86D4-B730C0385AE5Q34607093-99553DFD-F253-4FA1-B5A9-C4C42EA9A962Q34888756-D8A989BF-99EF-475A-A8D5-0E80D0D8500DQ34894843-785350B2-5EAD-45CC-A865-EB6BDB61E1D2Q34925321-801E9CFB-EC17-4EAB-AAC0-2DC8C36AA146Q35692942-DC319A4A-C227-40E7-9188-3361A8205E40Q35782702-29A3B7E0-0C0C-4BF7-B168-4F81586B6FF4Q35837448-6352F4E9-AD51-449E-8BE5-193EFC2A7002Q35838772-93929246-0AE6-4C6A-88BB-256AC73D14DDQ35840768-5C27D7D8-3960-4593-80F8-52792D1D3066Q35842465-3777A40E-F204-4E96-80E3-ED8B9BACEF75Q35845308-EFEEF549-51BF-42E6-A5D3-DD7FA044A71E
P2860
description
1991 nî lūn-bûn
@nan
1991 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
The biochemistry of AIDS.
@ast
The biochemistry of AIDS.
@en
The biochemistry of AIDS.
@nl
type
label
The biochemistry of AIDS.
@ast
The biochemistry of AIDS.
@en
The biochemistry of AIDS.
@nl
prefLabel
The biochemistry of AIDS.
@ast
The biochemistry of AIDS.
@en
The biochemistry of AIDS.
@nl
P1476
The biochemistry of AIDS.
@en
P2093
Vaishnav YN
Wong-Staal F
P304
P356
10.1146/ANNUREV.BI.60.070191.003045
P577
1991-01-01T00:00:00Z